Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Haematologica|February 14, 2007
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta geneChristoph Walz, Georgia Metzgeroth, Claudia Haferlach, et al.
Chemmedchem|March 27, 2014
Small-molecule inhibitors of AF6 PDZ-mediated protein-protein interactionsCarolyn Vargas, Gerald Radziwill, Gerd Krause, et al.
Developmental Biology|August 19, 2003
A sperm-activating peptide controls a cGMP-signaling pathway in starfish spermMidori Matsumoto, Johannes Solzin, Annika Helbig, et al.
BMC Cancer|April 8, 2020
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancerThomas Decker, Ulrike Söling, Antje Hahn, et al.
JAMA Network Open|March 11, 2020
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal CancerNorbert Marschner, Stefan Zacharias, Florian Lordick, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line SettingThomas Decker, Matthias Zaiss, Dunja Klein, et al.
Scientific Reports|July 18, 2025
Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1Nicole Naumann, Vito Dangelo, Johannes Lübke, et al.
International Journal of Cancer|December 21, 2024
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registryMarc Thill, Mark-Oliver Zahn, Anja Welt, et al.
International Journal of Cancer|March 18, 2026
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registryPatrick Marschner, Kai Ringwald, Marc Thill, et al.
Oncology Research and Treatment|November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B TrialManfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
Pageof 5